Marius Pharmaceuticals
Marius Pharmaceuticals is a Raleigh-based specialty biopharmaceutical company that develops and commercializes KYZATREX, the first FDA-approved oral testosterone undecanoate therapy, selling primarily direct-to-consumer at ~$170/month and through telehealth and specialty pharmacy partners to men with hypogonadism.
- Company typePrivate
- Founded2015
- HeadquartersRaleigh, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Marius Pharmaceuticals does
Marius Pharmaceuticals is a privately held, Raleigh, North Carolina-based specialty biopharmaceutical company (Delaware LLC) founded in 2015 that develops and commercializes treatments for testosterone deficiency and related hormone health conditions. Its core product is KYZATREX (testosterone undecanoate), an FDA-approved oral softgel testosterone replacement therapy launched in August 2022 in 100mg, 150mg, and 200mg dosage strengths. The proprietary formulation utilizes a phytosterol-based lymphatic absorption delivery system that bypasses first-pass liver metabolism, distinguishing it from injectable and topical alternatives; twice-daily dosing mimics the natural diurnal rhythm of endogenous testosterone, and clinical data show 88-96% of patients achieving normal testosterone levels at Day 90 with a low hypertension adverse event rate of 2-2.6%.
The company makes money primarily through direct-to-consumer pharmaceutical product sales of KYZATREX at approximately $170 per month without insurance coverage, supplemented by licensing and distribution partnerships for international markets (Hikma for Canada, Smartway for global early access, Numan for UK). Its go-to-market combines DTC e-commerce, telehealth platform distribution (Hims & Hers, The Vitamin Shoppe's Whole Health Rx), specialty pharmacy networks, men's health clinics (Gameday Men's Health), and government channels (Department of Veterans Affairs). Supporting the commercial effort is the ReThink Testosterone disease-state awareness initiative and disease-state campaigns targeting men with hypogonadism, metabolic comorbidities, Klinefelter's syndrome, and veterans, with active FDA regulatory advocacy that contributed to the February 2025 removal of the cardiovascular boxed warning on testosterone products.
The company is pursuing additional growth through geographic expansion (Canada, UK), indication expansion (women's health, older men 65-80, GLP-1 co-therapy muscle preservation), and a recently announced Marius AI initiative launched in May 2026 that positions the firm as what it calls the first AI-native pharmaceutical company. The IP portfolio comprises six U.S. patents with coverage extending to 2040 plus international grants across the EU, Canada, China, Taiwan, Japan, and New Zealand. The company is led by founder Himanshu H. Shah (Executive Chairman) and Shalin Shah (CEO), with Amit Shah as COO and Om Dhingra as Vice Chairman, and operates with 11-50 employees.
Marius Pharmaceuticals firmographics
Firmographics- Name
- Marius Pharmaceuticals
- Legal name
- Marius Pharmaceuticals, LLC
- Website
- https://mariuspharma.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Marius Pharmaceuticals is a Raleigh-based specialty biopharmaceutical company that develops and commercializes KYZATREX, the first FDA-approved oral testosterone undecanoate therapy, selling primarily direct-to-consumer at ~$170/month and through telehealth and specialty pharmacy partners to men with hypogonadism.
- Ownership category
- akta.pro rank
Marius Pharmaceuticals industry classification
Industry- Product category
- Testosterone Replacement Therapy
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where Marius Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Marius Pharmaceuticals business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Others
Revenue model
- Pharmaceutical Product Sales: Direct-to-consumer and partner-distributed sales of KYZATREX prescription medication. Launched in 2023 as a direct-to-consumer product without insurance coverage at approximately $170 per month.
- Licensing and Distribution Partnerships: International licensing agreements such as the Hikma Pharmaceuticals licensing agreement for Canadian market and regional partnerships for global expansion.
- International Early Access Program: Partnership with Smartway Pharmaceuticals for exclusive Early Access Provider arrangement in all countries outside the USA.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Monthly prescription at approximately $170 per month |
Go-to-market motion3 records
Distribution channels9 records
Marketing channels8 records
Marius Pharmaceuticals product offering
Product offeringCore offering
Marius Pharmaceuticals develops and sells KYZATREX (testosterone undecanoate), an FDA-approved oral testosterone replacement therapy in softgel capsule form for adult men with low or no testosterone due to certain medical conditions. The proprietary formulation is absorbed via the lymphatic system to bypass first-pass liver metabolism and is administered twice daily in 100mg, 150mg, and 200mg dosages. The company also distributes the product through telehealth partnerships, retail health channels, specialty pharmacies, and international licensing agreements.
Product overview
Marius Pharmaceuticals is a specialty pharmaceutical company focused on testosterone replacement therapy. The company's primary product is KYZATREX (testosterone undecanoate), an FDA-approved oral softgel capsule TRT launched in August 2022. The company operates alongside ReThink Testosterone, a companion disease-state awareness initiative that educates patients about testosterone deficiency and treatment options. The company has expanded internationally with Health Canada approval and is pursuing AI-native capabilities through Marius AI.
Differentiator
Problem solved
Functional benefit
Brands
- KYZATREX: FDA-approved oral testosterone replacement therapy (testosterone undecanoate) CIII capsules for adult men with low testosterone levels.
- ReThink Testosterone
Products and services
- KYZATREX (testosterone undecanoate) KYZATREX is an FDA-approved oral testosterone replacement therapy (TRT) in softgel capsule form, absorbed primarily via the lymphatic system to avoid liver toxicity. It is indicated for adult men with low or no testosterone due to certain medical conditions, administered twice daily with food in 100mg, 150mg, and 200mg dosages.
- Marius AI Marius AI is an AI-native pharmaceutical initiative launched by Marius Pharmaceuticals, positioning the company as the first AI-native pharmaceutical company.
Quantifiable outcome
- 88-96% of patients achieved normal testosterone levels at Day 90
- +4 more outcomes
Companies that use Marius Pharmaceuticals
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Marius Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Marius Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- Hikma PharmaceuticalscoreLicensing agreement for KYZATREX (testosterone undecanoate) CIII capsules in Canada. Enables Marius to expand market beyond the United States following Health Canada approval.
- FDA Expert PanelcoreCEO Shalin Shah invited to speak at landmark FDA Expert Panel on Testosterone Replacement Therapy for Men scheduled December 10, 2025. Significant regulatory engagement driving labeling updates.
- All-Female Advisory Board (Women's Health)minorFormation of all-female advisory board including medical experts in urology, gynecology, longevity, and regenerative medicine to guide testosterone research for women, especially post-menopause.
- Hims & Hers Health, Inc.coreMarius Pharmaceuticals and Hims & Hers collaboration to expand access to KYZATREX, the first FDA-approved oral testosterone therapy offered on the Hims & Hers platform. This partnership enables direct-to-consumer access through the Hims & Hers telehealth platform serving nearly 2.5 million subscribers.
- Major Academic Medical CenterminorPartnership with major academic medical center on education and research efforts for oral testosterone, supporting clinical development and medical education.
- US Specialists Management, LLC (USSM)minorPartnership with USSM through affiliated urologic in-office dispensaries, expanding specialty pharmacy distribution network.
- Gameday Men's HealthminorDistribution expansion collaboration with Gameday Men's Health, providing access through their men's health clinic network.
- nuBioAge and nuHxminorCollaborative GLP-1 comparison study in male patients. Partnership to study KYZATREX's ability to prevent muscle loss from Wegovy ( GLP-1 medications) with 40% of weight loss being lean muscle.
- NumanminorPartnership with UK-based Numan to combat testosterone deficiency with KYZATREX. Expands access to men in the UK market.
- The Vitamin ShoppecorePartnership to offer KYZATREX through The Vitamin Shoppe's Whole Health Rx telehealth platform powered by WellSync. Expands access to millions of American men experiencing testosterone deficiency through retail wellness channel.
- WellSynccoreTechnology partner powering The Vitamin Shoppe's Whole Health Rx telehealth platform. Provides virtual care platform connecting patients with licensed healthcare providers in real time.
- Smartway PharmaceuticalscoreSmartway appointed as exclusive Early Access Provider for KYZATREX in all countries outside the USA. Smartway provides early access, compassionate use, and named patient supply services with hubs across UK, EU, Middle East, USA, and India.
Scale indicators6 records
Recent moves8 records
Expansion highlights8 records
Marius Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Antares Pharma: Antares (now part of Halozyme) developed Tlando, an oral testosterone undecanoate product directly competing with KYZATREX in the same oral TRT category. Both companies target men with hypogonadism through similar regulatory pathways and compete for the same prescriber base.
- Tolmar Pharmaceuticals: Tolmar commercializes Jatenzo, another FDA-approved oral testosterone undecanoate and the closest direct competitor to KYZATREX. Both products use lymphatic absorption to avoid liver toxicity and compete for oral TRT market share.
- Clarus Therapeutics: Clarus Therapeutics developed Jatenzo (originally) and remains focused on oral testosterone therapies, directly competing with KYZATREX in the oral TRT space. Similar specialty pharma profile targeting hypogonadism.
Emerging players
- Acerus Pharmaceuticals: Acerus markets Natesto, a nasal testosterone replacement therapy, competing with KYZATREX for the same hypogonadism patient population through a differentiated non-oral delivery route. Similar specialty men's health focus.
Broad incumbents
- AbbVie (AndroGel): AbbVie markets AndroGel, the legacy topical testosterone gel that has historically dominated the TRT market. While not a direct oral competitor, it serves the same hypogonadism patients and represents the standard-of-care Marius is displacing.
- Endo Pharmaceuticals: Endo markets Aveed (testosterone undecanoate injection), an injectable testosterone undecanoate product. Operates in the same testosterone replacement therapy market and competes for the same hypogonadism patient base.
- Upsher-Smith Laboratories: Upsher-Smith markets Testim, a topical testosterone gel competing for hypogonadism patients. Specialty pharma with overlapping men's health franchise and similar commercial-stage profile.
Regional players
- Besins Healthcare: Besins manufactures AndroGel outside the US and other testosterone products globally, including in Europe and Asia. Comparable hormone therapy specialty pharma that Marius could eventually partner with or compete against in international markets.
Others
- Hims & Hers Health: Hims & Hers is both a partner and adjacent player; it offers competing men's health treatments including branded and generic testosterone therapies through its telehealth platform. Comparable as a DTC men's health channel rather than a direct therapeutic competitor.
- Hikma Pharmaceuticals: Hikma is the Canadian licensing partner for KYZATREX and a broad specialty/generic pharmaceutical company with overlapping men's health and endocrinology portfolios. Comparable as a specialty pharma distributor and adjacent therapeutic category player.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks1 record
Key highlights7 records
Customer concentration
Marius Pharmaceuticals social profiles
Digital presenceMarius Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Marius Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles12 records
Marius Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Marius Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Marius Pharmaceuticals
What does Marius Pharmaceuticals do?
Marius Pharmaceuticals develops and sells KYZATREX (testosterone undecanoate), an FDA-approved oral testosterone replacement therapy in softgel capsule form for adult men with low or no testosterone due to certain medical conditions. The proprietary formulation is absorbed via the lymphatic system to bypass first-pass liver metabolism and is administered twice daily in 100mg, 150mg, and 200mg dosages. The company also distributes the product through telehealth partnerships, retail health channels, specialty pharmacies, and international licensing agreements.
Is Marius Pharmaceuticals a public or private company?
Marius Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Marius Pharmaceuticals founded?
Marius Pharmaceuticals was founded in 2015. It employs 11 to 50 people.
Where is Marius Pharmaceuticals based?
Marius Pharmaceuticals is headquartered in Raleigh, United States, in the North America region.
How does Marius Pharmaceuticals make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Distribution Partnerships and international Early Access Program.
Who are Marius Pharmaceuticals's main competitors?
Direct peers on record are Antares Pharma, Tolmar Pharmaceuticals and Clarus Therapeutics. Acerus Pharmaceuticals is listed as an emerging player. Broad incumbents are AbbVie (AndroGel), Endo Pharmaceuticals and Upsher-Smith Laboratories. Besins Healthcare is listed as a regional player. Others are Hims & Hers Health and Hikma Pharmaceuticals.
Does Marius Pharmaceuticals have an API?
No public API is recorded for Marius Pharmaceuticals.
What industry is Marius Pharmaceuticals in?
Marius Pharmaceuticals's product category is Testosterone Replacement Therapy. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325411 and its SIC code is 2834.